2030년까지 북미 유방암 치료제 시장 예측 - 지역 분석 - 약물 치료[표적 약물 치료(Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab 및 기타 표적 약물 치료), 호르몬 약물 치료(선택적 에스트로겐 수용체 조절제, 아로마타제 억제제)별 및 선택적 에스트로겐 수용체 하향 조절제), 화학 요법 및 면역 요법/생물학적 요법], 유방암 유형(호르몬 수용체, HER2+ 및 삼중 음성 유방암) 및 유통 채널(병원 약국, 약국 및 소매 약국, 온라인 약국) )
맞춤형 의약품의 사용 증가로 북미 유방암 치료제 시장 성장 촉진
맞춤형 의약품에는 개별 환자에 맞게 치료 계획을 맞춤화하는 것이 포함됩니다 다른 요인들 중에서도 유전적 구성을 기반으로 합니다. 이 접근법은 각 환자의 암의 고유한 특성을 고려하므로 고도로 표적화되고 효과적인 치료를 가능하게 합니다. 유전체학 및 분자 진단의 발전으로 맞춤형 의학이 유방암 치료에서 실행 가능한 옵션이 되었습니다. 의료 서비스 제공자는 환자의 종양을 분자 수준에서 분석하여 암 성장을 촉진하는 특정 유전적 돌연변이나 바이오마커를 식별할 수 있습니다. 그런 다음 이 정보를 사용하여 특정 환자에게 가장 효과적일 수 있는 표적 치료법이나 면역 치료법과 같은 가장 적절한 치료 옵션을 선택할 수 있습니다. 유방암 치료에 맞춤형 의약품을 사용하면 환자 결과를 크게 향상시킬 수 있는 잠재력이 있습니다. 예를 들어, 2022년 2월 NIH 연구자들은 환자의 종양과 싸우는 면역 세포를 사용하여 전이성 유방암 환자를 치료하는 실험적 형태의 면역요법인 맞춤형 유방암 치료법을 개발하여 맞춤형 의학을 발전시켰습니다.
의료 서비스 제공자는 개별 환자에게 맞춤형 치료를 제공함으로써 성공적인 결과의 가능성을 높이고 불필요한 부작용의 위험을 줄일 수 있습니다. 환자 결과를 개선하는 것 외에도 맞춤형 의학은 경제적 이점도 제공합니다. 의료 서비스 제공자는 효과적일 가능성이 높은 치료법을 선택함으로써 비효과적인 치료법과 관련된 의료 비용을 줄이고 불필요한 비용을 피할 수 있습니다. 유전체학 및 분자 진단이 발전함에 따라 맞춤형 의학은 향후 점점 더 접근 가능해지고 표준 치료 프로토콜에 통합될 가능성이 높습니다. 따라서 맞춤형 의료의 사용 증가는 북미 유방암 치료제 시장에 새로운 성장 추세를 가져올 것으로 예상됩니다.
북미 유방암 치료제 시장 개요
북미 유방암 치료제 시장은 미국, 캐나다, 멕시코로 구분됩니다. 미국은 이 지역에서 가장 큰 시장 점유율을 보유하고 있습니다. 시장 성장은 주로 유방암 유병률 증가, 새로운 치료법 개발을 위한 R&D 투자 증가 등의 요인으로 인해 지속적인 성장이 예상되는 이 지역에 기인합니다. 또한 점점 더 많은 시장 참여자가 북미 국가에서 지리적 입지를 확장하고 있습니다.
의료 기술과 연구의 발전으로 환자의 치료 결과를 향상시킬 수 있는 획기적인 치료법이 개발되었습니다. 화이자, 노바티스, 로슈, 아스트라제네카, 엘리릴리 등 몇몇 대형 제약회사가 미국 유방암 치료제 시장을 장악하고 있다. 이들 기업은 새롭고 향상된 의약품을 시장에 출시하기 위해 연구 개발에 상당한 투자를 하고 있습니다. 정부가 시행하는 규제와 정책도 시장에 영향을 미친다. 유방암 치료를 위한 새로운 약물과 치료법은 식품의약청(FDA) 정부 기관의 승인을 받았습니다. 앞으로 유방암 치료제 시장은 더욱 확대될 것으로 예상된다.
2030년까지 북미 유방암 치료제 시장 수익 및 예측(미화 백만 달러)
북미 유방암 치료제 시장 세분화
북미 유방암 치료제 시장은 세분화되어 있습니다. 약물치료, 유방암 종류, 유통경로에 따라
북미 유방암 치료제 시장은 약물치료를 기준으로 표적약물치료, 호르몬약물치료, 화학요법, 면역치료/생물치료 등으로 구분된다. 표적 약물 치료 부문은 2022년에 더 큰 점유율을 차지했습니다. 표적 약물 치료 부문은 아베마시클립, 아도-트라스투주맙 엠탄신, 팔보시클립, 트라스투주맙 및 기타 표적 약물 치료로 더욱 세분화됩니다. 또한 호르몬 약물 치료 부문은 선택적 에스트로겐 수용체 조절제, 아로마타제 억제제 및 선택적 에스트로겐 수용체 하향 조절제로 분류됩니다.
북미 유방암 치료제 시장은 유방암 종류별로 호르몬수용체, HER2+ 유방암, 삼중음성유방암으로 구분된다. 2022년에는 호르몬 수용체 부문이 더 큰 점유율을 차지했습니다.
유통 채널별로 북미 유방암 치료제 시장은 병원 약국, 약국, 소매 약국, 온라인 약국으로 분류됩니다. 2022년에는 병원 약국 부문이 더 큰 점유율을 차지했습니다.
국가별로 북미 유방암 치료제 시장은 미국, 캐나다, 멕시코로 분류됩니다. 2022년 북미 유방암 치료제 시장은 미국이 장악했습니다.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Genentech Inc, Teva Pharmaceutical Industries Ltd와 Amgen Inc는 북미 유방암 치료제 시장에서 활동하는 선도적인 회사 중 일부입니다.
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Breast Cancer Therapeutics Market - Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market - North America Market Analysis
5.1 North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy
6.1 Overview
6.2 North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type
7.1 Overview
7.2 North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Breast Cancer Therapeutics Market - Regional Analysis
9.1 North America Breast Cancer Therapeutics Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 North America Breast Cancer Therapeutics Market, Breakdown, by Country, Revenue (2022) (US$ Million)
9.1.3 North America Breast Cancer Therapeutics Market, by Country
9.1.3.1 US
9.1.3.1.1 US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 US: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 US: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 US: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 US: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 US: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Canada
9.1.3.2.1 Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Canada: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Canada: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Canada: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Canada: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Canada: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 Mexico
9.1.3.3.1 Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 Mexico: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 Mexico: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 Mexico: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 Mexico: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 Mexico: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Amgen Inc
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. North America Breast Cancer Therapeutics Market Segmentation
Table 2. North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 4. US Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 5. US Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 6. US Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 7. US Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. US Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 19. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 20. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 21. Glossary of Terms, Breast Cancer Therapeutics Market
List of Figures
Figure 1. North America Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. North America Breast Cancer Therapeutics Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
Figure 5. North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. North America Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Growth Strategies in Breast Cancer Therapeutics Market
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Genentech Inc
9. Teva Pharmaceutical Industries Ltd
10. Amgen Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America breast cancer therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in North America breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution